JP5406934B2 - ジアリールピリミジン非ヌクレオシド系逆転写酵素阻害剤の合成方法 - Google Patents
ジアリールピリミジン非ヌクレオシド系逆転写酵素阻害剤の合成方法 Download PDFInfo
- Publication number
- JP5406934B2 JP5406934B2 JP2011537016A JP2011537016A JP5406934B2 JP 5406934 B2 JP5406934 B2 JP 5406934B2 JP 2011537016 A JP2011537016 A JP 2011537016A JP 2011537016 A JP2011537016 A JP 2011537016A JP 5406934 B2 JP5406934 B2 JP 5406934B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound represented
- synthesizing
- etravirin
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 38
- 230000015572 biosynthetic process Effects 0.000 title description 13
- 238000003786 synthesis reaction Methods 0.000 title description 13
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 title description 6
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 66
- 230000002194 synthesizing effect Effects 0.000 claims description 28
- 229960002049 etravirine Drugs 0.000 claims description 27
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 claims description 26
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 18
- YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 14
- 239000012442 inert solvent Substances 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 9
- 229910021529 ammonia Inorganic materials 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 6
- DPVIABCMTHHTGB-UHFFFAOYSA-N 2,4,6-trichloropyrimidine Chemical compound ClC1=CC(Cl)=NC(Cl)=N1 DPVIABCMTHHTGB-UHFFFAOYSA-N 0.000 claims description 5
- WFYGXOWFEIOHCZ-UHFFFAOYSA-N 4-hydroxy-3,5-dimethylbenzonitrile Chemical compound CC1=CC(C#N)=CC(C)=C1O WFYGXOWFEIOHCZ-UHFFFAOYSA-N 0.000 claims description 5
- 150000004703 alkoxides Chemical class 0.000 claims description 5
- 230000002140 halogenating effect Effects 0.000 claims description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 5
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 4
- 238000000354 decomposition reaction Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 2
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 description 30
- CMORVDDKOVDMDP-UHFFFAOYSA-N 4-[6-chloro-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=CC(Cl)=NC(NC=2C=CC(=CC=2)C#N)=N1 CMORVDDKOVDMDP-UHFFFAOYSA-N 0.000 description 11
- 229940124821 NNRTIs Drugs 0.000 description 11
- -1 IV Chemical class 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006482 condensation reaction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 0 *c(c(O)nc(*)n1)c1O Chemical compound *c(c(O)nc(*)n1)c1O 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IVIJQBJPKVPGJT-UHFFFAOYSA-N 4-(2,6-dichloropyrimidin-4-yl)oxy-3,5-dimethylbenzonitrile Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=CC(Cl)=NC(Cl)=N1 IVIJQBJPKVPGJT-UHFFFAOYSA-N 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000005658 halogenation reaction Methods 0.000 description 3
- BTDGLZSKNFJBER-UHFFFAOYSA-N 2-(4-cyanophenyl)guanidine Chemical compound NC(=N)NC1=CC=C(C#N)C=C1 BTDGLZSKNFJBER-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000498 cooling water Substances 0.000 description 2
- ZEDPQIJYJCPIRM-UHFFFAOYSA-N dimethyl benzonitrile Natural products CC1=CC=CC(C#N)=C1C ZEDPQIJYJCPIRM-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- AQSQFWLMFCKKMG-UHFFFAOYSA-N 1,3-dibutylurea Chemical compound CCCCNC(=O)NCCCC AQSQFWLMFCKKMG-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical class NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 description 1
- VYQXVCMPWXPVNF-UHFFFAOYSA-N 2-hydroxy-3,5-dimethylbenzonitrile Chemical compound CC1=CC(C)=C(O)C(C#N)=C1 VYQXVCMPWXPVNF-UHFFFAOYSA-N 0.000 description 1
- CHZCERSEMVWNHL-UHFFFAOYSA-N 2-hydroxybenzonitrile Chemical class OC1=CC=CC=C1C#N CHZCERSEMVWNHL-UHFFFAOYSA-N 0.000 description 1
- BOEANPBQSJMFAW-UHFFFAOYSA-N 3,4-di(propan-2-yl)-2H-pyran-2-amine Chemical compound C(C)(C)C1=C(C(OC=C1)N)C(C)C BOEANPBQSJMFAW-UHFFFAOYSA-N 0.000 description 1
- DUFGYCAXVIUXIP-UHFFFAOYSA-N 4,6-dihydroxypyrimidine Chemical compound OC1=CC(O)=NC=N1 DUFGYCAXVIUXIP-UHFFFAOYSA-N 0.000 description 1
- QELKPCHCXREHAE-UHFFFAOYSA-N 4-[6-amino-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=CC(N)=NC(NC=2C=CC(=CC=2)C#N)=N1 QELKPCHCXREHAE-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- GKTWIIVEUYLSCS-UHFFFAOYSA-N 5-bromo-2,4,6-trichloropyrimidine Chemical compound ClC1=NC(Cl)=C(Br)C(Cl)=N1 GKTWIIVEUYLSCS-UHFFFAOYSA-N 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000008856 allosteric binding Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- RPXWNTQJYTYNJO-UHFFFAOYSA-M sodium 4-cyano-2,6-dimethylphenolate Chemical compound [Na+].CC1=CC(C#N)=CC(C)=C1[O-] RPXWNTQJYTYNJO-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
(1)2,4,6−トリクロロピリミジンと3,5−ジメチル−4−ヒドロキシベンゾニトリルとを縮合させて式(V)で表される化合物を得るステップと、
(2)4−アミノベンゾニトリルと縮合させて、式(V)で表される化合物を式(VI)で表される化合物に変換するステップと、
(3)式(VI)で表される化合物を加アンモニア分解して、式(IV)で表される化合物を得るステップと、
(4)式(IV)で表される化合物をハロゲン化して、エトラビリンを得るステップと、を含む。
(1)塩基及び不活性溶媒の存在下で、2,4,6−トリクロロピリミジンと3,5−ジメチル−4−ヒドロキシベンゾニトリルとを縮合させて式(V)で表される化合物を得るステップと、
(2)アルコキシドを塩基として使用して、4−アミノベンゾニトリルと縮合させて、式(V)で表される化合物を式(VI)で表される化合物に変換するステップと、
(3)任意で、式(VI)で表される化合物を精製するステップと、
(4)式(VI)で表される化合物を加アンモニア分解して、式(IV)で表される化合物を得るステップと、
(5)不活性溶媒中で、式(IV)で表される化合物をハロゲン化して、エトラビリンを得るステップと、を含む。
4−[(2,6−ジクロロ)−4−ピリミジニルオキシ]−3,5−ジメチルベンゾニトリル(化合物V)の合成
2,4,6−トリクロロピリミジン(100g,0.545モル)を1,4−ジオキサン(300ml)に溶解し、3,5−ジメチル−4−ヒドロキシベンゾニトリル(80.1g,0.545モル)を攪拌しながら添加した。N,N−ジイソプロピルエチルアミン(141.00g,1.09モル)を30分掛けて添加した。反応液を70℃で加熱し、2時間攪拌した。反応液をゆっくり15℃まで冷却し、得られた生成物を12〜15℃でろ過したのち、ろ過ケーキを50mlの1,4−ジオキサンで洗浄した。最後に、ろ過ケーキを水(200ml)で洗浄し、目的物を得た。融点:208〜210℃ 収量:128g 収率(%):80%
4−[[6−クロロ−2−[(4−シアノフェニル)アミノ]−4−ピリミジニル]オキシ]−3,5−ジメチルベンゾニトリル(化合物VI)の合成
化合物V(100g,0.34モル)をN−メチルピロリドン(500ml)に溶解し、4−アミノベンゾニトリル(40.12g,0.34モル)を攪拌しながら添加した。反応液を0℃に冷却した。この溶液に、カリウムtert−ブトキシド(76.3g,0.68モル)を0〜10℃で小分けで1時間掛けて添加した。反応液を1〜2時間、室温まで放置冷却した。反応液温度を20℃未満に保持しながら、反応液を冷却水(2.0L)にゆっくり添加した。反応液をろ過して、ろ過ケーキを200mlの水で洗浄した。
ウェットケーキを再び20℃未満の水1.0Lに溶解し、ろ過した。得られた生成物を60〜70℃で酢酸エチル300mlで2回洗浄した後、10〜15℃でろ過した。収量:50g
4−[[6−アミノ−2−[(4−シアノフェニル)アミノ]−4−ピリミジニル]オキシ]−3,5−ジメチルベンゾニトリル(化合物(IV)の合成
25%アンモニア水(600ml)を化合物VI(100g,0.266モル)の1,4−ジオキサン溶液(1000ml)に添加し、反応液を圧力オートクレーブ内で120℃で加熱し、10〜12時間120〜125℃に保持した。反応液を50℃まで放置冷却し、再び70〜80℃に加熱した。このとき、水(200ml)をゆっくり添加した。反応液を徐々に10℃まで冷却したのち、ろ過してウェットケーキを得た。これを乾燥させて目的物を得た。収量:75g 収率(%):80%
エトラビリンの合成
化合物(IV)(100g,0.28モル)をメチレンジクロリド(800ml)に添加し、0〜5℃に冷却した。メチレンジクロリド200mlに溶解して、液状臭素(47.2g,0.294モル)を0〜5℃でゆっくり添加した。反応液を0〜5℃で2〜4時間攪拌した。冷却水(800ml)を反応液に添加し、0〜5℃でゆっくり水酸化ナトリウム溶液を添加してpHを9〜10に調整した。メタ重亜硫酸ナトリウムを0〜5℃で添加して反応液のpHを8〜9に保持しながら、反応液を0〜10℃で1時間攪拌した。
反応液をろ過して、ろ過ケーキを200mlの水で洗浄した。ウェットケーキを50〜60℃で乾燥した後、アセトンで再結晶した。収量:100g 融点:252〜254℃
Claims (10)
- 前記ステップ(a)は不活性溶媒及び塩基の存在下で行われる、請求項2に記載のエトラビリンの合成方法。
- 前記不活性溶媒は1,4−ジオキサンであり、前記塩基としてN,N−ジイソプロピルエチルアミンを使用する、請求項3に記載のエトラビリンの合成方法。
- 前記塩基はカリウムtert−ブトキシドである、請求項1または2に記載のエトラビリンの合成方法。
- 前記ステップ(b)は、エタノール、N−メチル−2−ピロリドン、N,N−ジメチルホルムアミド、1,4−ジオキサン、テトラヒドロフラン、ジメチルスルホキシド、テトラリン、スルフォラン、及び、アセトニトリルから選ばれる不活性溶媒中で行われる、請求項1または2に記載のエトラビリンの合成方法。
- 前記不活性溶媒はN−メチル−2−ピロリドンである、請求項6に記載のエトラビリンの合成方法。
- 前記ステップ(c)は酢酸エチル洗浄により行われる、請求項1または2に記載のエトラビリンの合成方法。
- 前記ステップ(d)は、アンモニア水溶液を使用して1,4−ジオキサン中で120〜130℃で行われる、請求項1または2に記載のエトラビリンの合成方法。
- 前記ステップ(e)は遊離ハロゲンを使用して行われる、請求項1または2に記載のエトラビリンの合成方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1479MU2009 | 2009-06-22 | ||
IN1479/MUM/2009 | 2009-06-22 | ||
PCT/IN2010/000422 WO2010150279A2 (en) | 2009-06-22 | 2010-06-18 | Process for synthesis of diarylpyrimidine non-nucleoside reverse transcriptase inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012509314A JP2012509314A (ja) | 2012-04-19 |
JP5406934B2 true JP5406934B2 (ja) | 2014-02-05 |
Family
ID=43386984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011537016A Expired - Fee Related JP5406934B2 (ja) | 2009-06-22 | 2010-06-18 | ジアリールピリミジン非ヌクレオシド系逆転写酵素阻害剤の合成方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20110196156A1 (ja) |
EP (1) | EP2342186B1 (ja) |
JP (1) | JP5406934B2 (ja) |
AP (1) | AP2858A (ja) |
BR (1) | BRPI1004934A2 (ja) |
CO (1) | CO6430461A2 (ja) |
ES (1) | ES2527103T3 (ja) |
IL (1) | IL214862A (ja) |
RU (1) | RU2556986C2 (ja) |
UA (1) | UA106972C2 (ja) |
WO (1) | WO2010150279A2 (ja) |
ZA (1) | ZA201108690B (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8153790B2 (en) | 2009-07-27 | 2012-04-10 | Krizmanic Irena | Process for the preparation and purification of etravirine and intermediates thereof |
GR1007010B (el) | 2009-10-08 | 2010-10-07 | Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), | Ινσουλινοειδη πεπτιδια |
EP2702045B1 (en) | 2011-04-26 | 2017-10-18 | Mylan Laboratories Ltd. | Novel process for the preparation of etravirine |
WO2012170647A1 (en) * | 2011-06-09 | 2012-12-13 | Assia Chemical Industriew Ltd. | Process for the preparation of etravirine and intermediates in the synthesis thereof |
WO2013059572A1 (en) | 2011-10-19 | 2013-04-25 | Assia Chemical Industries Ltd. | Process for the preparation of etravirine and intermediates in the synthesis thereof |
CN103373965B (zh) * | 2012-04-24 | 2016-04-27 | 上海迪赛诺药业有限公司 | 依曲韦林及其中间体的制备方法 |
WO2013159286A1 (zh) * | 2012-04-24 | 2013-10-31 | 上海迪赛诺药业有限公司 | 依曲韦林及其中间体的制备方法 |
CN102675220B (zh) * | 2012-05-28 | 2014-03-19 | 南京药石药物研发有限公司 | 一种制备依曲韦林的方法及其中间体 |
CN104447573B (zh) * | 2014-11-27 | 2016-11-09 | 山东大学 | 一种依曲韦林的制备方法 |
RU2728555C1 (ru) * | 2019-12-24 | 2020-07-30 | Общество с ограниченной ответственностью "Балтфарма" | Способ получения этравирина |
CN111675661B (zh) * | 2020-06-28 | 2021-08-24 | 山东大学 | 一种含有反式双键的二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100658489B1 (ko) | 1998-11-10 | 2006-12-18 | 얀센 파마슈티카 엔.브이. | Hiv 복제를 억제하는 피리미딘 |
JP4919566B2 (ja) * | 1999-09-24 | 2012-04-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗ウイルス組成物 |
TW200626560A (en) * | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines |
US20090124644A1 (en) * | 2005-01-27 | 2009-05-14 | Janssen Pharmaceutica N.V. | Hiv inhibiting 2-(4-cyanophenylamino) pyrimidine derivatives |
MX2007010051A (es) * | 2005-02-18 | 2007-09-21 | Tibotec Pharm Ltd | Derivados de oxido de 2-(4-cianofenilamino)pirimidina que inhiben el virus de inmunodeficiencia humana. |
PT1858861E (pt) * | 2005-03-04 | 2010-09-16 | Tibotec Pharm Ltd | 2-(4-cianofenil)-6-hidroxilaminopirimidinas inibidoras do hiv |
EP2044037A2 (en) * | 2006-07-24 | 2009-04-08 | Gilead Sciences, Inc. | Hiv reverse transcriptase inhibitors |
WO2010131118A2 (en) * | 2009-05-12 | 2010-11-18 | Pliva Hrvatska D.O.O. | Polymorphs of etravirine and processes for preparation thereof |
-
2010
- 2010-06-18 ES ES10791750.2T patent/ES2527103T3/es active Active
- 2010-06-18 RU RU2011129982/04A patent/RU2556986C2/ru not_active IP Right Cessation
- 2010-06-18 AP AP2011005715A patent/AP2858A/xx active
- 2010-06-18 EP EP10791750.2A patent/EP2342186B1/en not_active Not-in-force
- 2010-06-18 JP JP2011537016A patent/JP5406934B2/ja not_active Expired - Fee Related
- 2010-06-18 US US12/998,295 patent/US20110196156A1/en not_active Abandoned
- 2010-06-18 UA UAA201108835A patent/UA106972C2/uk unknown
- 2010-06-18 WO PCT/IN2010/000422 patent/WO2010150279A2/en active Application Filing
- 2010-06-18 BR BRPI1004934A patent/BRPI1004934A2/pt not_active Application Discontinuation
-
2011
- 2011-08-28 IL IL214862A patent/IL214862A/en not_active IP Right Cessation
- 2011-11-25 ZA ZA2011/08690A patent/ZA201108690B/en unknown
- 2011-12-28 CO CO11179941A patent/CO6430461A2/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
UA106972C2 (uk) | 2014-11-10 |
IL214862A (en) | 2015-07-30 |
EP2342186A4 (en) | 2012-03-21 |
AP2011005715A0 (en) | 2011-06-30 |
CO6430461A2 (es) | 2012-04-30 |
WO2010150279A3 (en) | 2011-02-24 |
ES2527103T3 (es) | 2015-01-20 |
WO2010150279A2 (en) | 2010-12-29 |
BRPI1004934A2 (pt) | 2016-11-29 |
ZA201108690B (en) | 2013-01-30 |
AP2858A (en) | 2014-02-28 |
US20110196156A1 (en) | 2011-08-11 |
RU2556986C2 (ru) | 2015-07-20 |
IL214862A0 (en) | 2011-11-30 |
RU2011129982A (ru) | 2013-01-27 |
EP2342186A2 (en) | 2011-07-13 |
EP2342186B1 (en) | 2014-09-17 |
JP2012509314A (ja) | 2012-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5406934B2 (ja) | ジアリールピリミジン非ヌクレオシド系逆転写酵素阻害剤の合成方法 | |
JP5491589B2 (ja) | 化学的プロセス | |
CA2848631C (en) | Rilpivirine hydrochloride | |
US8153790B2 (en) | Process for the preparation and purification of etravirine and intermediates thereof | |
CA2834257C (en) | Process for rilpivirine | |
JP2011515372A (ja) | 置換ピリミジン類の位置選択的製造法 | |
JP5580385B2 (ja) | 4−[(1,6−ジヒドロ−6−オキソ−2−ピリミジニル)アミノベンゾニトリルの製造方法 | |
CA2307770A1 (en) | Novel carboxylic acid derivatives which carry amide side chains, production of said carboxylic acid derivatives and their use as endothelin receptor antagonists | |
JP2012523444A (ja) | 内皮受容体アンタゴニスト(ボセンタン)を調製するための方法 | |
EP2702045B1 (en) | Novel process for the preparation of etravirine | |
WO2012011129A2 (en) | Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt | |
JP4501015B2 (ja) | アミノピリミジン化合物の製造方法 | |
CN101475535A (zh) | 多取代n-daco类衍生物及其合成方法及用途 | |
WO2014068588A2 (en) | Process for the synthesis of etravirine and its intermediates | |
JPWO2005019225A1 (ja) | Nk1受容体拮抗作用を有する化合物の製造方法及びその製造中間体 | |
CA2379545A1 (en) | Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130909 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131008 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131101 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5406934 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |